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Abstract: Medication non-adherence in patients with schizophrenia continues to be a 
significant problem and threatens successful treatment outcomes. Medication non-adherence is 
often associated with negative consequences, including symptom exacerbation, more frequent 
emergency room visits, re-hospitalizations and relapse. Long-acting injectable (LAI) forms of 
antipsychotics allow for rapid identification of non-adherence, obviate the need for the patient 
to take the medication on a daily basis and increase adherence to some significant degree. Eli 
Lilly has developed a long-acting depot formulation of olanzapine, olanzapine pamoate, which 
has recently been approved by the FDA for the US market, and which will be reviewed here. 
Olanzapine LAI appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 
300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 
150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance 
treatment of stable patients. Oral supplementation appears not to be needed, particularly not 
at the onset of treatment with the LAI as is necessary with risperidone LAI. Its efficacy is in 
general comparable to the efficacy seen with oral olanzapine at a corresponding dose. The side 
effect profile is also comparable to the side effects observed with oral olanzapine, including 
lower rates of extrapyramidal symptoms, prolactin elevation and cardiovascular side effects, 
but significant metabolic effects. The latter include significant weight gain, lipid abnormalities 
and glucose dysregulation. While the injection site adverse events are overall mild, the most 
significant serious adverse event is the post-injection delirium sedation syndrome (PDSS). While 
rare, this syndrome results from inadvertent intravascular injection of olanzapine LAI and can 
cause a range of olanzapine overdose-type of symptoms. Olanzapine LAI needs therefore to be 
administered by trained personnel in settings where a post-injection observation period for at least 
3 hours by medical personnel is available. The overall use of olanzapine LAI will probably be 
limited by the possibility of a PDSS event. Patients who have a history of good response to oral 
olanzapine and are in need of assured medication administration may present a good indication 
for its use, provided that the appropriate mental health delivery setting is available.
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Introduction
Medication non-adherence in patients with schizophrenia continues to be a significant 
problem and threatens successful treatment outcomes.1 Reported rates of non-adherence 
to antipsychotics range from 20% to 69% with an estimated average rate of about 50%.2,3 
Medication non-adherence is often associated with negative consequences, including 
symptom exacerbation, more frequent emergency room visits, re-hospitalizations and 
relapse.4 Among patients who discontinue their medication, 75% experience significant 
symptom exacerbation over 1 year compared to 25% of those who adhere to their Neuropsychiatric Disease and Treatment 2010:6 262
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medication.4 In turn, symptom exacerbation can often lead 
to serious consequences, including dangerous behaviors, 
worsened prognosis of the disease, antipsychotic treatment 
resistance and increased healthcare costs.4
Medication status is the largest predictor of relapse risk in 
schizophrenia with continuous maintenance of antipsychotic 
medication resulting in an approximate 70% reduction in the 
risk of relapse.3,4
Hence, treatments that can increase medication 
adherence are critically important in the pharmacological 
treatment of schizophrenia. Long-acting injectable (LAI) 
forms of antipsychotics fulfill an important role in this 
domain of treatment. LAI antipsychotics allow for rapid 
identification of non-adherence, obviate the need for the 
patient to take the medication every day and increase adher-
ence to some significant degree.2,3
Both typical antipsychotics (fluphenazine and haloperidol 
decanoate) and 2 atypicals (risperidone LAI and paliperidone 
palmitate) are available in the US as LAI formulations. Clini-
cians need a wider range of long-acting depot compounds to 
choose from within the atypical range of antipsychotics as, at 
present, only 1 atypical is available as a LAI antipsychotic. 
Risperidone LAI and paliperidone LAI are closely related 
to the same molecule.
Eli Lilly has developed a long-acting depot formulation 
of olanzapine, olanzapine pamoate (Zyprexa® Relprevv), 
which has been approved by the Food and Drug Adminis-
tration (FDA) and introduced in the US in 2010. We will 
review in the following sections its pharmacology and mode 
of action, its efficacy and safety profile and its place among 
the present second-generation LAI formulations.
Methods
The terms olanzapine pamoate and olanzapine long-acting 
injectable were systematically searched for on pubmed as 
well as on www.clinicaltrials.gov up to September 2009. 
In addition, the FDA website http://www.dfda.gov was 
queried for any available data on these topics. Finally, the 
Eli Lilly website was reviewed for any additional reported 
data on olanzapine pamoate. The following meetings were 
reviewed for reports on olanzapine LAI: Annual Meeting of 
the Society of Biological Psychiatry, Washington DC, 2008; 
Annual Meeting of the American Psychiatric Association, 
Washington DC, 2008, San Francisco CA, 2009; Annual 
Meeting of the NCDEU, Phoenix, AZ, 2009. Four peer 
reviewed studies were found on olanzapine pamoate,5–8 
4 entries on www.clinicaltrials.gov9–12 and 8 abstracts of 
poster presentations.13–20 It is important to note that until 
September 2009 few peer reviewed publications were 
available on the efficacy and safety of olanzapine pamoate, 
which somewhat limits this review.
Pharmacology and mode of action
Olanzapine LAI is the salt of pamoic acid and olanzapine 
that is suspended in an aqueous solution and is injected into 
the gluteal muscle.19 Once injected in the gluteal muscle, 
the two components of the salt slowly dissociate into 
separate molecular compounds, olanzapine and pamoic 
acid. The rate of dissolution of the salt is slow, allowing 
for a gradual release of olanzapine into the circulation over 
2 to 4 weeks.9 Other depot antipsychotic preparations use 
different mechanisms in order to achieve a slow absorption 
over time. A number of first-generation LAI antipsychot-
ics possess a terminal alcohol (-OH) group, which allows 
them to be combined with carboxylic acids by a process of 
esterification. Long-chain esters show high oil solubility and 
low water solubility. Long-acting injectable formulations of 
these drugs contain long-chain drug esters (eg, decanoate) 
dissolved in a vegetable oil. When injected intramuscularly, 
the oil forms a depot of drug: the drug ester slowly diffuses 
into the blood stream and is then rapidly hydrolyzed to release 
the parent drug. Most second-qeneration antipsychotics 
lack terminal -OH groups suitable for esterification. Modi-
fication of release characteristics is brought about by other 
means: encapsulating the drug into a biodegradable polymer 
(risperidone) or injecting a suspension (ie, water-insoluble par-
ticulate matter in water) of drug compound (olanzapine).21
The optimal time to peak concentration should 
be short to minimize the need for bridging with oral 
antipsychotic. Risperidone LAI (Risperdal® Consta®; 
Janssen Pharmaceuticals Ltd) uses microspheres which 
dissolve gradually and release the active compound into 
circulation. The absorption is slow and only reaches peak 
plasma levels after 2 weeks and requires therefore a transi-
tion with oral risperidone for 2 weeks initially. The absorp-
tion of paliperidone LAI is based on the palmitate ester 
of paliperidone, which is an aqueous suspension utilizing 
nanocrystal molecules. This formulation increases its sur-
face area and leads to initial rapid medication release and 
in a short time to steady state. Active paliperidone plasma 
levels are detected systemically at day one. The slow rate of 
dissolution of paliperidone palmitate results in a longer half-
life that ranges from 25 to 49 days, allowing a once-monthly 
intramuscular injection schedule. The first-generation anti-
psychotics haloperidol and prolixin use ester formations with 
a decanoate, which dissolve slowly over time.Neuropsychiatric Disease and Treatment 2010:6 263
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Pharmacokinetics
The doses of olanzapine LAI were chosen based on 
pharmacokinetic and safety results of phase I studies.9,13,19 
Specific pharmacokinetic data have been reported in an 
open label study in 282 stable patients with schizophre-
nia.3 Patients received doses of olanzapine LAI at 100 mg, 
150 mg, 160 mg, 200 mg and 300 mg every 2 weeks, and 
at 210 mg, 255 mg, 300 mg and 405 mg every 4 weeks for 
24 weeks. Olanzapine plasma concentrations increased 
2- to 3-fold with multiple dosing reaching eventually 
steady state after about 3 months of dosing. Olanzapine 
plasma concentrations were sustained throughout the 
2- and 4-week injection intervals. Maximum olanzapine 
plasma concentrations and area under the concentration 
vs time curve were proportionate to the LAI dose. Time 
to peak concentration after the injection was 4 days with a 
half-life of approximatively 26 days. This is an important 
pharmacokinetic feature as the time to onset of action after 
an injection is an important criterion for the clinician. 
The distribution of olanzapine plasma concentration after 
olanzapine LAI doses of 210 mg every 2 weeks, 300 mg 
every 2 weeks and 405 mg every 4 weeks were within 
the 10th and 90th percentiles of the range of olanzapine 
plasma concentrations found with the olanzapine oral 
formulation dosed at 5 mg once daily (10th percentile) 
and 20 mg once daily (90th percentile). Going from oral to 
olanzapine LAI, Gulliver et al19 recommend the following 
conversion strategies: for patients stabilized on 10 mg per 
day of oral olanzapine the starting olanzapine LAI dose 
should be 210 mg every 2 weeks or 405 mg every 4 weeks. 
The patient can then be reduced after 2 months to a lower 
maintenance dose of 150 mg every 2 weeks or 300 mg every 
4 weeks. For patients stabilized on 15 mg of oral olanzapine 
the starting olanzapine LAI dose should be 300 mg every 
2 weeks, which after 2 months can be reduced to 210 mg or 
405 mg every 4 weeks. For patients stabilized on 20 mg of 
oral olanzapine the starting dose of olanzapine LAI should 
be 300 mg every 2 weeks and should remain at that level, 
if clinically indicated.
The olanzapine pamoate salt dissolves much more 
rapidly when it is in contact with a larger amount of blood 
or plasma, resulting in the release of a large amount of 
olanzapine over a shorter period of time. Therefore, if olan-
zapine LAI is accidentally injected into vascular or capillary 
rich tissue, this property can result in very high olanzapine 
plasma levels rapidly after the injection with significant 
clinical acute morbidity. This observation underlies the 
post-injection delirium/sedation syndrome (PDSS) seen in 
the context of use of olanzapine LAI. It has been observed 
in clinical trials and will be reviewed below.
Receptor binding data
Mamo et al6 reported results on a study examining D(2) 
receptor occupancy of olanzapine LAI during a multicenter, 
open-label study exploring D(2) receptor occupancy of a 
fixed dose of olanzapine LAI given every 4 weeks. Patients 
with schizophrenia or schizoaffective disorder previously 
stabilized on oral olanzapine were switched to olanzapine 
LAI 300 mg by intramuscular injection every 4 weeks for 
6 months. No within-group significant changes were found 
in scores of the Brief Psychiatric Rating Scale Total or in 
the Clinical Global Impressions-Severity of Illness score, 
although 7 patients received oral olanzapine supplementation 
during the first four injection cycles. To minimize impact 
on D(2) occupancy by the supplemental oral olanzapine, 
positron emission tomography (PET) scans were not 
completed during injection cycles that required supplemental 
oral olanzapine. Mean striatal D(2) receptor occupancy, 
as measured by [(11) C]-raclopride PET, was 69% on oral 
olanzapine (5–20 mg/day) and 50% (trough) on olanzapine 
LAI at steady state. Following an initial decline, occupancy 
returned to 84% of baseline oral olanzapine occupancy after 
6 injections. Over the study period, D(2) receptor occupancy 
and plasma olanzapine concentrations were significantly 
correlated (r = 0.76, P = 0.001). Olanzapine LAI resulted 
in mean D(2) receptor occupancy of approximately 60% 
or higher at the end of the 6-month study period,6,22 a level 
consistent with antipsychotic efficacy and also found during 
treatment with oral olanzapine. However, supplemental oral 
olanzapine or another dosing strategy may be necessary to 
maintain adequate therapeutic response during the first few 
injection cycles.
Efficacy and safety studies
Acute treatment
One large, double-blind, placebo controlled, 8-week study of 
olanzapine LAI in 404 inpatients with acute schizophrenia 
patients compared 210 mg every 2 weeks, 300 mg every 
2 weeks, 405 mg every 4 weeks and placebo in a 1:1:1:1 
randomized design.5 All three olanzapine doses separated 
significantly from placebo on the total Positive and Negative 
Syndrome Scale (PANSS). The two higher doses separated 
from placebo on the PANSS at day 3, while all three doses 
separated at day 7 from placebo. Discontinuation rates were 
32% for the 210 mg dose, 33% for the 300 mg dose, 28% 
for the 405 mg dose and 43% for the placebo group. The Neuropsychiatric Disease and Treatment 2010:6 264
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mean daily benzodiazepine dose used during the trial was not 
statistically significantly different in the four treatment groups. 
There were no in-between group differences in the incidence 
of use of anticholinergics between the four groups; 8.2% of 
the placebo group patients received anticholinergics, while 
5.0% to 12.3% of the olanzapine LAI group patients received 
anticholinergics. Sedation and increased appetite were more 
frequently reported for the 300 mg group than for the placebo 
group. The three olanzapine groups showed a significantly 
higher change in mean weight gain compared to placebo 
(3.2–4.8 vs 0.3 kg; P  0.001), a significantly greater increase 
in fasting cholesterol values as compared to placebo (5.5–10.4 
vs –7.0 mg/dL; P  0.15) and a significantly greater increase 
in fasting triglycerides in the 210 mg and the 400 mg groups 
compared to placebo (26.3–30.3 vs –9.4 mg/mL; P  0.16), 
but not for the 300 mg group (17.6 mg/dL; P = 0.55). Few 
injection site reactions were reported and no patient dropped 
out of the study because of injection site reaction.
In a more recent post-hoc comparison of these study 
results with a corresponding set of three studies of oral 
olanzapine, haloperidol and placebo in similarly acutely ill 
patients, olanzapine LAI was found to show a comparable 
magnitude of symptom reduction compared to patients 
treated with a dose range of 2.5 mg to 15 mg oral olanzapine 
during 6 weeks of treatment. It appeared that the incidence 
of parkinsonism was slightly lower for olanzapine LAI with 
2.3% to 6.2%, while it was 7.8% to 18.5% for oral olanzapine 
and 41.8% to 52.5% for haloperidol.18
Maintenance treatment
Olanzapine LAI was compared to oral olanzapine for the 
maintenance of antipsychotic response in stable outpatients 
with schizophrenia in a 24-week double-blind study.7,14 
Patients were assigned in a partial randomization design 
to the following treatment groups: olanzapine LAI 405 mg 
every 4 weeks, 300 mg every 2 weeks, 150 mg every 2 weeks 
(total N = 318) or 45 mg/4 weeks (N = 141) or to oral 
olanzapine 10 mg, 15 mg, or 20 mg/day (N = 144) without 
a placebo group. The oral olanzapine group assignment 
was constrained by whichever oral dose patients had been 
  stabilized on before entering the trial for 4 to 8 weeks. 
Each of the olanzapine LAI doses was statistically superior 
to the olanzapine LAI 45 mg every 4 weeks dose group 
based on time to exacerbation. In addition, the three active 
olanzapine LAI dose groups showed effective maintenance 
of response as measured by PANSS scores as compared 
to the 45 mg/4 week group, which showed a statistically 
significant worsening. Significant separation between the 
olanzapine LAI dose groups 300 mg every 2 weeks, 405 mg 
every 4 weeks, 150 mg every 2 weeks groups versus the 
45 mg every 4 weeks group in PANSS total scores was also 
observed starting at 3, 2, and 11 weeks, respectively, and 
was maintained through the end of the study (P  0.05). 
Similar differences between the three active olanzapine LAI 
dose groups and the 45 mg every 4 weeks dose group were 
observed for the Brief Psychiatric Rating Scale total, Clinical 
Global Impressions-Improvement, and Clinical Global 
Impressions-Severity (CGI-S) scores. Mean baseline to 
endpoint change in PANSS total score for the oral olanzapine 
group was -1.7, which was not significantly different from 
that of the highest olanzapine LAI dose group (300 mg 
every 2 weeks = -2.2; P = 0.606), but superior to the other 
olanzapine LAI doses (P  0.01). The pooled 150 mg 
and 300 mg every 2 weeks olanzapine LAI groups were 
non-inferior to their corresponding oral olanzapine dose 
groups in terms of the non-exacerbation rate over 24 weeks 
(90% vs 93% respectively). Conversely, the three active 
olanzapine LAI groups (405 mg; 300 mg; 150 mg) showed 
non-inferiority as compared to the oral olanzapine groups 
in terms of exacerbation of symptoms.
Treatment related adverse events leading to discontinuation 
were overall low and comparable over the four olanzapine LAI 
groups (3.1%, 2.8%, 5.0% and 4.2%). Clinically significant 
weight gain from baseline to endpoint was approximatively 
dose related: 15.2%, 20.7%, 16.4% and 8.3%. There were 
significant increases in total cholesterol and fasting LDL 
cholesterol in the three active olanzapine LAI groups over the 
low dose group of 45 mg every 4 weeks, while no significant 
in-between group differences in change were seen in fasting 
triglyceride and glucose levels. There was a non-significant 
increase of shifts from 150 mg/dL to high in fasting triglyc-
eride levels seen in the olanzapine LAI 300 mg every 2 weeks 
group compared to the other three olanzapine LAI groups. No 
significant differences in treatment emergent extrapyramidal 
symptoms were reported between any of the olanzapine LAI 
dose groups and the overall rate of extrapyramidal symp-
toms was low throughout the trial. Incidence of injection 
site reactions was low (2.8%). However, 2 patients treated 
with olanzapine LAI experienced PDSS following possible 
inadvertent intravascular injection.
Interim results from another long-term, open-label 
safety extension study of olanzapine LAI with maximum 
treatment duration of 190 weeks were recently reported.15 
Patients were 18 to 75 years of age with schizophrenia 
or schizoaffective disorder (N = 931) who were followed 
up after completing 1 of 3 randomized, controlled studies Neuropsychiatric Disease and Treatment 2010:6 265
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of olanzapine LAI, in which patients had been randomly 
assigned to oral olanzapine, olanzapine LAI, or placebo. 
During the open-label extension, all patients received 
flexibly-dosed olanzapine LAI at injection intervals of 
approximately 2 to 4 weeks. At the time of the report, the 
rate of study discontinuation was 46.3%. Discontinuation 
rate at 18 months was 34.3%. The most common reasons 
for discontinuation were: subject decision (23.4%), adverse 
event (6.7%), and lost to follow-up (5.7%). Adverse events 
in 5% of patients were increased weight, insomnia, anxiety, 
somnolence, headache, and nasopharyngitis. Of note were 
26 occurrences of PDSS following possible accidental 
  intravascular injection of a portion of the dose; all of the 
patients fully recovered within 72 hours.
Mean weight change was +1.88 kg, with 32.1% of patients 
experiencing clinically significant weight gain. Percentages of 
patients who showed an increase from normal to high on fast-
ing glucose, random total cholesterol, or random triglycerides 
were 5.5%, 5.2%, and 14.3%, respectively. Mean CGI-S 
scores remained stable throughout the open label follow-up 
of the three studies (2.9 at baseline to 2.8 at endpoint).
Switching studies
Two switching strategies from oral antipsychotics to 
olanzapine LAI were compared in a recent report:16,17 a 
direct switch from the previous antipsychotic to olanzap-
ine LAI versus taper of previous antipsychotic medication 
during the first 2 weeks of treatment. Analyses were based 
on 8-month data from an ongoing 2-year open-label study of 
olanzapine LAI in outpatients considered at risk for relapse 
(N = 264) who received olanzapine LAI every 4 weeks with 
a starting dose of 405 mg and flexible dosing thereafter. 
Investigators, at their discretion, could either directly switch 
patients or taper their previous antipsychotic medication 
during the first 2 weeks of treatment. At the time of study 
entry, 62 patients were receiving typical antipsychotics, 188 
were receiving atypical antipsychotics (76 receiving oral 
olanzapine), and 34 were not receiving any antipsychotic; a 
total of 16 were on prior injectable antipsychotic medication. 
Some patients were taking more than one antipsychotic 
at baseline. Of a total of 264 patients, 150 (56.8%) were 
switched directly and the rest were tapered. The two groups 
did not significantly differ in discontinuation rates (direct: 
29.3% vs taper: 28.9%, P ∼ 1.0) and there was no significant 
difference between the two groups on PANSS total score 
mean change at any visit up to 8 months (direct: -1.5, taper: 
-3.4, P = 0.785, from a mean baseline of 56.7 [SD = 9.8]). 
Treatment-emergent adverse events in 5% of patients 
were: increased weight (10.2%), insomnia (8.3%), anxiety 
(6.8%), somnolence (6.8%), and increased appetite (5.7%). 
The switch groups did not significantly differ in mean weight 
change (P = 0.419), with an average weight gain of 2.0 kg, nor 
did they significantly differ in terms of laboratory analytes or 
other safety parameters. There did not appear to be clinically 
significant differences for those who were directly switched 
to olanzapine LAI versus those who were tapered.
Post-injection syndrome
A small number of patients have experienced PDSS dur-
ing the participation in olanzapine LAI trials, which is a 
serious adverse event. The signs and symptoms include 
feelings of tiredness, dizziness and fatigue progressing to 
delirium and or excessive sedation and are probably related 
to an inadvertent intravascular injection of part or the entire 
olanzapine LAI dose. In a poster by the manufacturer, all 
safety data of all completed or ongoing olanzapine LAI 
trials were pooled up to data lock up to May 31 2008.20 
Twenty-nine cases (in 28 patients) of PDSS were identified 
and reviewed. The per-injection rate was calculated based 
on a total of 40,000 injections as 0.07% and a per-patient 
rate of 1.2%. The cumulative risk of experiencing an episode 
of PDSS after 1 year of treatment was 07% to 1.2%. The 
presenting symptoms were consistent with excessive sys-
temic levels of olanzapine LAI, such as sedation, dizziness, 
confusion, slurred speech, altered gait, weakness, muscle 
spasms and/or unconsciousness. Two patients experienced 
significant blood pressure increases, but no other changes 
in vitals signs were observed. Time to onset varied between 
0 to 300 minutes with a mean of 48 minutes. Eighty percent 
of PDSS events occurred within 1 hour after the injection, 
17% occurred between 1 hour to 3 hours and 1 case occurred 
after 3 hours. 79% of patents experiencing a PDSS event 
were hospitalized and received either only observational care 
or supportive medical care. Pharmacokinetic data collected 
at the time of the event revealed that olanzapine plasma 
  concentrations were much higher than expected relative to the 
post injection concentration previously collected for the same 
patients. There was no relationship of the PDSS event and any 
concomitant medications. All patients recovered completely 
after 3 to 72 hours. PDSS occurred at any injection time point 
as it was observed from the first injection to the 66th injection. 
It is interesting to note that PDSS like events have not been 
reported with other long-acting depot antipsychotics.
The pathophysiology of the PDSS is most likely related 
to the observation that the olanzapine pamoate salt dissolves 
much more rapidly when it is in contact with a larger amount Neuropsychiatric Disease and Treatment 2010:6 266
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of blood or plasma, releasing therefore a large amount of 
olanzapine over a short period of time. Hence, if olanzapine 
LAI is accidentally injected into vasculature or capillary rich 
tissue, this property can result in very high olanzapine plasma 
levels leading to the symptoms of PDSS.
Special precautions need to be taken therefore when 
using olanzapine LAI. First, proper injection technique needs 
to used, which includes deep gluteal injection and aspiration 
of the syringe for 5 seconds in order to verify that no blood 
is being aspired. In the event of blood being aspired the 
injection site needs to be changed, the syringe needs to be 
discarded and a new dose needs to be reconstituted. After the 
injection the patient needs to be observed for 3 hours at the 
facility where the injection was administered, and the patient 
needs to be accompanied home by an informed person. 
Instructions for the patient need to include information 
about the symptoms of PDSS, the avoidance of driving or 
operating machinery.20
The overall use of olanzapine LAI will probably be 
limited by the potential occurrence of a PDSS event. The 
primary settings where olanzapine LAI will be utilized will 
be settings where the post-injection observation period can 
be implemented and easily integrated into the usual service 
delivery process, such as inpatient settings, day hospitals or 
day programs where patients can be involved in active group 
activities and are at the same time under observation by a 
mental health care provider after the injection.
The Committee for Medicinal Products for Human Use 
in Europe has recommended approval of olanzapine LAI in 
September 2008, which was subsequently approved by the 
European Commission for maintenance treatment of adult 
patients with schizophrenia sufficiently stabilized during 
acute treatment with oral olanzapine for the European 
Community countries. In contrast, the FDA has delayed a 
decision on approval as recently as September 2009. The 
Agency has requested that Eli Lilly and Company pre-
pare a proposed risk evaluation and mitigation strategy. In 
February 2009 the FDA had issued a not-approvable letter, 
saying it required additional information about the risk 
and cause of excessive sedation observed in some patients. 
Finally, olanzapine LAI was approved by the FDA with a 
black box warning in 2010. The specific requirements are 
that olanzapine LAI must be administered in a registered 
healthcare facility with ready access to emergency response 
services. After each injection, patients must be observed at 
the healthcare facility by a healthcare professional for at least 
3 hours. Because of this risk, olanzapine LAI is available only 
through a restricted distribution program called ZYPREXA 
RELPREVV Patient Care Program and requires prescriber, 
healthcare facility, patient, and pharmacy training.
Comparison with other long-acting 
antipsychotics
No data have yet been published on head-to-head randomized 
trials comparing olanzapine LAI with other antipsychotic 
depot preparations. There is, however, a virtual comparison 
examining completion rates of olanzapine LAI studies and 
of studies with risperidone (RLAI) in LAI formulations. 
Completion rates were used as a proxy of overall efficacy 
during the 12-month open-label treatment of patients with 
schizophrenia.8 Two comparisons of 12-month completion 
rates were made: (1) between the two OLAI and RLAI 
studies which had the most similar study design and patient 
characteristics; and (2) in all relevant OLAI and RLAI stud-
ies identified. For the first comparison, 12-month completion 
rates for olanzapine LAI and RLAI were 81.5% and 52.0% 
(P  0.001), respectively, for the subgroup of the studies, 
which included the most similar populations with regard to 
baseline treatment and patient characteristics. For the second 
comparison, 12-month completion rates were 72.9% and 
58.0% (P  0.001), respectively, for all patients included 
in Study HGKB and a pooled analysis of all relevant RLAI 
studies. No individual RLAI study had a 12-month completion 
rate greater than that seen for OLAI. However, these results 
have to be tempered given the potential imbalance between 
populations across the selected studies.
Conclusions
This review is somewhat limited by the fact that few peer 
reviewed publications are as yet available on the efficacy 
and safety of olanzapine pamoate. Overall, olanzapine LAI 
appears to be an effective antipsychotic at dosages of 210 mg 
every 2 weeks, 300 mg every 2 weeks and 405 mg every 
4 weeks in patients with acute schizophrenia, and at 150 mg 
every 2 weeks, 300 mg every 2 weeks and at 405 mg every 
4 weeks for the maintenance treatment of stable patients with 
schizophrenia. Its efficacy is in general comparable to the 
efficacy seen with oral olanzapine at a corresponding dose. 
The side effect profile is also comparable to the side effects 
observed with oral olanzapine, including lower rates of extra-
pyramidal symptoms, prolactin elevation and cardiovascular 
side effects, but significant metabolic effects. The latter ones 
include significant weight gain, lipid abnormalities (increase 
in cholesterol, low-density lipoprotein cholesteraol levels and 
triglycerides) and glucose dysregulation. While the injection 
site adverse events are overall mild, the most significant serious Neuropsychiatric Disease and Treatment 2010:6
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adverse event is the PDSS. While rare, this syndrome results 
from inadvertent intravascular injection of olanzapine LAI and 
can cause a range of olanzapine overdose-type of symptoms. 
Olanzapine LAI needs therefore to be administered by trained 
  personnel in settings where a post-injection observation period 
for at least 3 hours by medical personnel is available. The 
  overall use of olanzapine LAI will probably be limited by the 
  possibility of a PDSS event. Patients who have a history of 
good response to oral olanzapine and are in need of assured 
medication administration may present a good indication for 
its use, provided that the appropriate mental health delivery 
setting is available.
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